By Jesse Greenspan (February 24, 2011, 7:19 PM EST) -- Units of Novartis AG and Hisamitsu Pharmaceutical Co. Inc. accused Mylan Inc. of infringing two of their patents by seeking to market a generic estradiol transdermal system in a pair of lawsuits filed this week.
One of the suits, lodged Thursday in the U.S. District Court for the District of Vermont, took Mylan and two subsidiaries to task over an abbreviated new drug application they submitted to the U.S. Food and Drug Administration.
A nearly identical suit was filed two days earlier in the U.S. District Court for the Southern District of New York.
According to Mylan's Paragraph IV certification, the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!